



Alethia Biotherapeutics

## **Alethia Biotherapeutics Announces Issuance of a Japanese Patent for Monoclonal Antibodies Targeting Siglec-15.**

**MONTREAL, February 19, 2013** – Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies, announced today that the Company has been granted its first Japanese patent related to Siglec-15 entitled “Polynucleotides and Polypeptide Sequences Involved in the Process of Bone Remodeling” (Patent No. 5173838). This patent covers monoclonal antibodies that target Siglec-15 as “composition of matter” and the use of these antibodies for modulating osteoclast differentiation and for treating bone resorption. Yves Cornellier, President & CEO of Alethia commented, “We are very pleased with the issuance of this new patent. It underscores the strength of our intellectual property portfolio in our bone anti-resorptive program”.

Alethia has demonstrated that Siglec-15 is an important regulator of osteoclast differentiation and function. The Company’s bone anti-resorptive program was purposefully designed to develop a new generation of therapies that decrease osteoclast activity while maintaining bone formation.

Dr. Mario Filion, Chief Scientific Officer of Alethia commented, “This patent, in addition to several other patents recently issued in the US and Europe, illustrate the robustness of our discovery approach for innovative clinically-relevant therapeutic targets. Data from pre-clinical *in vivo* models of bone loss demonstrated that the results obtained with Siglec-15 antibodies are distinctive from those obtained with other anti-resorptive therapies. In particular, inhibition of Siglec-15 resulted in sustained anti-resorptive activity coupled with maintenance of bone formation, a profile that, if translated in the clinic, would differentiate this product from currently marketed drugs”..

### **About Alethia Biotherapeutics Inc.**

Alethia is a privately held, Montreal-based biotechnology company created in 2002. Alethia develops monoclonal antibody therapeutics against novel clinically relevant targets identified using its patented STAR discovery technology. Alethia is well funded with top-tier investors committed to the success of the Company notably, Agechem Venture Fund, BDC Capital and GO Capital.

### **Contacts**

Yves Cornellier  
President and CEO  
[ycornellier@alethiabiotech.com](mailto:ycornellier@alethiabiotech.com)  
Tel: (514) 858-7666 ext. 206

Mario Filion, Ph.D.  
Executive VP, CSO  
[mariof@alethiabiotech.com](mailto:mariof@alethiabiotech.com)  
Tel: (514) 858-7666 ext.207